This won’t materially move the MRK NYSE stock price, as this stoppage / null-result was likely long ago priced in, as Baxter, Pfizer and Lilly have seen the same blind alley appear, in their respective programs.
Alzheimer’s is a very, very tough nut to crack — it seems to be thousands of small things, at work — not just one or two main bio-chemical processes. So, a pill for the memory eroding scourge will elude us for the foreseeable future… according to Rahway, thus via SeekingAlpha, and the fine but subscription based Endpoints News:
…A spokesperson for Merck told Endpoints News that data from the trials suggested that MK-1942 was linked to potential liver toxicity as detected by abnormal changes in liver function tests in several participants.
“No related serious adverse events were reported,” the company added….
There you have it. Yes, human health care science is… science. Trial and error. Rinse… and repeat. But ever, onward.
नमस्ते
